Literature DB >> 3124731

Influence of cation supplements on activity of netilmicin against Pseudomonas aeruginosa in vitro and in vivo.

A L Barry1, G H Miller, C Thornsberry, R S Hare, R N Jones, R R Lorber, R Ferraresi, C Cramer.   

Abstract

In vitro studies were performed with 74 Pseudomonas aeruginosa isolates which were collected during a multicenter trial. The isolates were obtained from 70 patients who had been treated with netilmicin as the only antipseudomonal antibiotic. Clinically, 83% of the patients were cured or improved, and 64% of the Pseudomonas isolates were eliminated by chemotherapy. The 74 clinical isolates and 38 additional isolates with known mechanisms of aminoglycoside resistance were tested in three separate laboratories by disk diffusion methods and by microdilution tests with three broth media (Mueller-Hinton broth with full, half, and no cation supplements). Isolates that responded to netilmicin therapy and those that failed to respond were all susceptible by the disk test, and most were susceptible by microdilution tests with unsupplemented broth. However, over half of the clinical isolates appeared to be resistant when cations were added to the broth medium. Strains capable of producing enzymes that inactivate netilmicin were resistant by all methods tested. Broth dilution and agar dilution results were most comparable when half of the recommended cation supplements was added to Mueller-Hinton broth. Further consideration should be given to reducing the concentration of cations that are added to Mueller-Hinton broth when netilmicin susceptibility tests are being performed. However, additional studies with other aminoglycosides are needed before appropriate testing conditions can be standardized.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3124731      PMCID: PMC174981          DOI: 10.1128/AAC.31.10.1514

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media.

Authors:  L B Reller; F D Schoenknecht; M A Kenny; J C Sherris
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

2.  Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism.

Authors:  V M Zimelis; G G Jackson
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

3.  Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa.

Authors:  A L Barry; G H Miller; R S Hare; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-03       Impact factor: 5.948

4.  Cation components of Mueller-Hinton agar affecting testing of Pseudomonas aeruginosa susceptibility to gentamicin.

Authors:  M A Kenny; H M Pollock; B H Minshew; E Casillas; F D Schoenknecht
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

5.  Effect of medium composition on the apparent sensitivity of Pseudomonas aeruginosa to gentamicin.

Authors:  L P Garrod; P M Waterworth
Journal:  J Clin Pathol       Date:  1969-09       Impact factor: 3.411

6.  Effect of cation content of agar on the activity of gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.

Authors:  J A Washington; R J Snyder; P C Kohner; C G Wiltse; D M Ilstrup; J T McCall
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

  6 in total
  9 in total

Review 1.  Functions and activities of the Area Committee on Microbiology of the National Committee for Clinical Laboratory Standards.

Authors:  J A Washington
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

2.  Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides.

Authors:  A L Barry; L B Reller; G H Miller; J A Washington; F D Schoenknect; L R Peterson; R S Hare; C Knapp
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

3.  Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity.

Authors:  R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Wide variability in Pseudomonas aeruginosa aminoglycoside results among seven susceptibility testing procedures.

Authors:  J L Staneck; S Glenn; J R DiPersio; P A Leist
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

5.  Comparison of the Sceptor Pseudomonas Plus MIC Panel with agar dilution for susceptibility testing of Pseudomonas aeruginosa.

Authors:  L F Joyce; K Stockman; J Downes; J H Andrew
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

6.  Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa.

Authors:  L F Joyce; J Downes; K Stockman; J H Andrew
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

7.  Aminoglycoside resistance among Pseudomonas aeruginosa isolates with an unusual disk diffusion antibiogram.

Authors:  R B Clark; C C Sanders; C B Pakiz; M K Hostetter
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

8.  Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo-β-Lactamase-Producing Enterobacteriaceae.

Authors:  Anastasia Bilinskaya; Douglas J Buckheit; Michael Gnoinski; Tomefa E Asempa; David P Nicolau
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

9.  Influence of biofilm growth age, media, antibiotic concentration and exposure time on Staphylococcus aureus and Pseudomonas aeruginosa biofilm removal in vitro.

Authors:  Xiaofeng Chen; Trine Rolighed Thomsen; Heinz Winkler; Yijuan Xu
Journal:  BMC Microbiol       Date:  2020-08-24       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.